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Isolation of Stenotrophomonas maltophilia virus
Bfi1: a biofilm inhibiting phage

BY
Thomas Edward Moran

Department of Biological Sciences
College of Science and Health
DePaul University, Chicago, Illinois

ABSTRACT
The bacterium Stenotrophomonas maltophilia is an emerging infectious pathogen of
global concern. Due to its drug-resistant nature, there are limited treatment options available. A
potential option for combating S. maltophilia infections is phage therapy, the medicinal use of
viruses to treat bacterial infections. Stenotrophomonas phage Bfi1 was isolated from a soil
sample using S. maltophilia clinical strain S18202. Transmission electron microscopy provided
evidence that this phage is a member of the Siphoviridae family. Host range analysis showed that
the phage successfully infected and lysed 30% of the S. maltophilia strains tested. Genomic
analysis revealed that the phage contains approximately 32.2-56.5 kbp dsDNA. This phage was
assessed for its ability to affect biofilm formation. At an MOI≥103, the phage inhibited S18202
biofilm formation after 24 h incubation with the phage. To the best of our knowledge, this is the
first time the effects of a bacteriophage on S. maltophilia biofilms have been studied.
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I. INTRODUCTION
Stenotrophomonas maltophilia: An Opportunistic Pathogen
Stenotrophomonas maltophilia is a species with a complex taxonomic history. This species of
bacteria was first described in 1943 by J.L. Edwards (Hugh and Ryschenkow, 1961). At the
time, the species was named Bacterium bookeri (Hugh and Ryschenkow, 1961). Since its
original characterization, it was reclassified as Pseudomonas maltophilia due to its physiological
characteristics, including multitrichous flagella (Hugh and Ryschenkow, 1961). Later, the
species was classified as a Xanthomonas sp. (Swings et al., 1983). The authors cited DNA-rRNA
hybridization data, among other genotypic and phenotypic characteristics, as major influences
for this reclassification. Because of the unique phenotypes of P. maltophilia, adding it to the
taxonomic group, Xanthomonas, altered the definition of this genus (Palleroni and Bradbury,
1993). To resolve this conflict, a new bacterial genus, Stenotrophomonas, was named; this is
where S. maltophilia is currently classified. This history is important as earlier publications use
these different names in their work. Additionally, it demonstrates the relatedness of S.
maltophilia to other bacterial pathogens, such as Pseudomonas aeruginosa or Xanthomonas
campestris, a human and plant pathogen, respectively.
S. maltophilia is found throughout the world (Brooke, 2012). There is evidence that the
species can live in a wide range of moist environments. It has been isolated from many
environments, including plant roots and soil, river water, tap water, vertebrates, and invertebrates
(Nakatsu et al., 1995; Denton et al., 2003; Hejnar et al., 2007; Romanenko, 2008; Berg, 2009).
Its ability to live in diverse environments makes it a concern, because there are many sources
from which an infection can be acquired. While nosocomial infections are common, a review of
several studies from various health networks (United States, Australia, Taiwan, Canada,
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Germany) estimated that 22 % of S. maltophilia infection cases are community-acquired
(Falagas et al., 2009).
This bacterium is an opportunistic pathogen. This means it is not highly infectious, but it
can cause disease in humans when the normal host barriers have been penetrated (Brooke,
2012). S. maltophilia causes diseases in patients with compromised immune systems, such as
patients with cancer or cystic fibrosis (CF) (Chang et al., 2015). It has been the causative agent
of bacteremia, biliary sepsis, meningitis, and urinary tract infections, among other infections
(Nguyen and Muder, 1994; Papadakis et al., 1995; Vartivarian et al., 1996; Araoka et al., 2010).
In general, these infections are life-threatening. In one hospital survey of S. maltophilia
infections, the reported mortality rate was 60% (Nseir et al., 2006).
As a pathogen, evidence indicates that S. maltophilia is a growing concern. SENTRY
Antimicrobial Surveillance Program studies show that over time the prevalence rates of
S. maltophilia respiratory tract infections (RTIs) increased from 3.3%-3.5% during 1997-2004
to 4.4% during 2009-2012 (Gales et al., 2001; Hoban et al., 2003; Jones, 2010; Sader et al.,
2014). These studies showed that S. maltophilia moved from the eighth most common cause
of RTIs to the sixth in the United States. Additionally, of non-enteric Gram-negative bacilli,
S. maltophilia ranks globally as the third most commonly isolated pathogen from any
infection (Sader and Jones, 2005). These data demonstrate that S. maltophilia should not be
overlooked, because a significant number of infections result from this pathogen with
increasing frequency.
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Use of Antibiotics
The primary treatment for S. maltophilia infections is antibiotic therapy. Currently healthcare
professionals recommend trimethoprim-sulfamethoxazole (TMP-SMX) (Chang et al., 2015).
This antibiotic is used primarily because resistance to TMP-SMX is not common. One
surveillance study (2009-2012) found that 96% of US isolates and 98% of European isolates
were susceptible to TMP-SMX (Sader et al., 2014). For patients with contraindications for TMPSMX, the fluoroquinolone levofloxacin is recommended (Chang et al., 2015). There are concerns
that the efficacy of levofloxacin is not as high as TMP-SMX. However, two retrospective studies
reported no statistical difference in outcome between these two antibiotic approaches (Cho et al.,
2014; Wang et al., 2014). These two antibiotics are currently considered to be effective therapies
for S. maltophilia infections.
Despite the efficacy of levofloxacin and TMP-SMX, there are long-term concerns with
antibiotic therapy. Worldwide susceptibility of S. maltophilia to levofloxacin has decreased
from 83.4 % (2003-2008) to 77.3% (2011) (Farrell et al., 2010; Sader et al., 2013). Additionally,
resistance to TMP-SMX has been identified (Toleman et al., 2007). As S. maltophilia infection
rates increase, one can expect that antibiotic resistance will rise.

Antibiotic Resistance Genes of S. maltophilia
S. maltophilia is naturally resistant to many antibiotics. It has been suggested that this natural
resistance may arise from selection pressures that arise from a plant commensal lifestyle. High
levels of competition and exposure to natural antibiotics and secondary antimicrobial metabolites
are strong evolutionary drivers that contribute to this resistance (Berg and Martinez, 2015).
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Within the genome of S. maltophilia, the genes that facilitate the breakdown or removal
of antibiotics play a major role in antibiotic resistance. L1 and L2 are β-lactamases encoded in
the S. maltophilia genome (Crossman et al., 2008). L1 hydrolyses all β-lactams except aztreonam
(a monobactam) (Paton et al., 1994). L2 hydrolyses all penicillins, all cephalosporins in the first,
second and third generations, and aztreonam (Walsh et al., 1997). Several aminoglycosidemodifying enzymes have been described in S. maltophilia strains. These enzymes include
AAC(6’)Iz, APH(3’)-IIc, AAC(6’)-Iak, and AAC(6’)-Iam (Li et al., 2003; Okazaki and Avison,
2007; Crossman et al., 2008; Tada et al., 2014). Drug efflux pumps also play a major role in
antibiotic resistance. A recent analysis of the genome of S. maltophilia K279a identified four
efflux pumps involved in antibiotic resistance: SmeABC SmeDEF, SmeIJK, and SmeYZ
(Alonso and Martinez, 2000; Li et al., 2002; Crossman et al., 2008). These efflux pumps
contribute to resistance of a broad range of antibiotics, including β-lactams, aminoglycosides,
quinolones, tetracyclines, macrolides, chloramphenicol, novobiocin, and TMP-SMX (Wang et
al., 2018).
While some resistance mechanisms involve the breakdown or effluxion of antibiotics, the
S. maltophilia genome also contains genes whose encoded proteins resist the mechanisms of
action of antibiotics. The sul2 gene encodes for a dihydropteroate synthase which is not
inhibited by sulfonamides. Strains that have class 1 integrons and insertion sequence common
region elements that were linked to the gene sul2 are resistant to TMP-SMX (Toleman et al.,
2007). Sulfonamides, like sulfamethoxazole ,work by binding to the active site of
dihydropteroate synthase, which is involved in folic acid synthesis, converting p-aminbenzoate
to dihydropteroic acid. The sul2 codes for a dihydropteroate synthase that has a weak binding
affinity for sulfonamides (Sköld, 2000). Variants of dfr genes, that code for dihydrofolate
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reductase, are also associated with high levels of resistance to TMP-SMX (Hu et al., 2011).
Dihydrofolate reductase is an enzyme involved in DNA synthesis. Trimethoprim binds to
dihydrofolate reductase to inhibit its function. Variants in the dfr genes lead to weaker binding
by this enzyme to trimethoprim and consequently lead to resistance to this drug (Sköld and
Widh, 1974).
The chromosomal qnr gene has been associated with quinolone resistance in
S. maltophilia. Quinolones target DNA gyrase, an enzyme that relieves tension of supercoiling
during DNA replication (Champoux, 2001). The antibiotic forms a stable complex with the DNA
and DNA gyrase, preventing the progression of DNA replication (Hiasa and Shea, 2000). The
qnr gene encodes a protein that can bind specifically to the gyrase holoenzyme in the DNA
binding groove. This prevents the deleterious effects of the stabilized quinolone, DNA, and
DNA gyrase complex (Hooper and Jacoby, 2015). By doing so, Qnr has demonstrated its
importance in low-level resistance to quinolones (Sánchez and Martínez, 2010).
Resistance to polymyxins can be attributed to the gene, spgM. This gene encodes a
phosphoglucomutase involved in lipopolysaccharide (LPS) synthesis. Bacterial mutants that lack
spgM have less LPS when compared to SpgM+ cells (McKay et al., 2003). Polymyxin selectively
binds to LPS and destabilizes the outer membrane enough to penetrate. Ultimately, the antibiotic
causes lysis of the host by destroying the integrity of the cell’s inner membrane (Yu et al., 2015;
Malinowski et al., 2017). With less LPS, there are fewer targets for the antibiotic’s action.

Biofilms of S. maltophilia
Along with possessing antibiotic resistance genes, S. maltophilia can form biofilms. A biofilm is
an accumulation of microbial cells that are associated with a surface and enclosed in a
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polysaccharide matrix (Donlan, 2002). Biofilms are formed when, individual, free-floating cells
(referred to as planktonic cells), adhere to a surface. The cells replicate, form a monolayer, and
begin to secrete a polysaccharide matrix (extracellular polymeric substance) outside of the cell
(Gupta et al., 2016). S. maltophilia can form biofilms on a variety of surfaces. S. maltophilia can
form biofilms on glass, plastics, and host tissue (Jucker et al., 1996; de Oliveira-Garcia et al.,
2003).
Biofilms have been shown to facilitate antibiotic resistance in two ways. First,
extracellular polymeric matrices act as a physical barrier. For example, extracellular matrix
components in P. aeruginosa biofilms can impede penetration of the antibiotic ciprofloxacin
into cells living within the biofilm (Suci et al., 1994). The biofilm acts to shield the cells within
the structure.
The second mechanism of biofilm resistance relates to variation in the cell populations of
a biofilm. Because cells in a biofilm have access to differing nutrient levels, there is
heterogeneity in the cellular metabolic rates within the population (Burrowes et al., 2011). Some
cells with little nutrient access exist in slow-growing or starved states. These are referred to as
persister cells. Since antibiotics often target the pathways involved in actively growing and
dividing cells, persister cells are not affected by these antimicrobials (Costerton et al., 1999).

Bacteriophages
The ability for S. maltophilia to persist, despite antibiotic treatments has led to a need for
alternative therapies, and directed an interest in the research of bacteriophages. Often referred
to as phages, they are defined as viruses that infect a bacterial host (Labrie et al., 2010). They
usually come in two forms, lytic (or virulent) and lysogenic (or temperate). Upon infection by a
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lytic phage, the virus takes over the host’s machinery and replicates itself (Labrie et al., 2010).
At the end of the lytic cycle, the host cell is lysed to release viral progeny (Labrie et al., 2010).
When a temperate phage infects their host, the phage DNA is incorporated into the
genome of the host, becoming a prophage (Labrie et al., 2010). Inside the host, the virus can
remain dormant and is transmitted vertically to host daughter cells (Labrie et al., 2010). Under
certain conditions, the prophage can be activated via induction to enter into a lytic cycle and lyse
the host cell (Labrie et al., 2010).
A third, less common form of phage infection is known as pseudolysogeny. During
pseudolysogeny, the infection of the host is stalled. The viral nucleic acids do not replicate as it
would in a lytic cycle or integrate as it would in a lysogenic cycle (Ripp and Miller, 1997). It is
present in the host in an inactive state.
Lytic phages have drawn a lot of interest from researchers concerned with antibiotic
resistance. Because the lytic cycle is inherently lethal to the bacterial host, physicians could
potentially use phages to treat and prevent bacterial infections in humans. Prior to the discovery
of antibiotics, phages were documented as being used in the treatment of infections (Abedon et
al., 2011). This legacy has continued in several countries in Western Europe, including Georgia
and Poland (Abedon et al., 2011).
Phage therapies may offer many advantages over antibiotic therapies. A major benefit is
that phages have a limited effect on resident flora. Phages usually only infect organisms of the
same species. The breadth of strains or species which can be infected by a virus is referred to as
the viral host range. The fact that many phages are shown to have limited host ranges means the
killing of off-target bacteria is minimized (Abedon et al., 2011). This results in a lower potential
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for side effects brought about by dysbiosis, the disturbance to gut microbiota homeostasis
(DeGruttola et al., 2016).
The abundance of phages is another benefit to be considered. Estimations by phage
ecologists have determined that the number of phage particles found in soil is on average 1.5 x
108 g-1 (Ashelford et al., 2003). In aquatic environments, it has been estimated that there are
approximately 100-300 phage strains ml-1 (Wommack et al., 1999). This means that there are
potentially many undescribed phages in these habitats that have yet to be assessed for
therapeutic use. In the case that a bacterial pathogen develops resistance to one phage, there are
many other phages that may cause host lysis.

S. maltophilia Phages
To the best of our knowledge, there have been six lytic and pseudolysogenic S. maltophilia
bacteriophages described in the literature to date. Of the described lytic phages, four are
myoviruses, phiSMA5 (Chang et al., 2005), Smp14 (Chen et al., 2007), and S3 (García et al.,
2008), DLP6 (Peters et al., 2017), one is a podovirus, IME15 (Huang et al., 2012), and one is a
siphovirus DLP2 (Peters et al., 2015). Each of these phages has a double stranded (ds) DNA
genome. At the time of writing, these reported phages represent the entire library of phages with
potential to be used in treatments for S. maltophilia infections.
The first lytic phage to be characterized was phiSMA5 (Chang et al., 2005). The phage
was determined to have a dsDNA genome that is ~250 kbp and contains at least 25 proteins
(Chang et al., 2005). Smp14 was the first phage to have its genome partially sequenced (Chen et
al., 2007). The genome is estimated to be ~160 kbp and consists of at least 20 unique proteins.
Phage S3 was found to have a genome of ~33 kbp (García et al., 2008). The DNA of phage S3
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was resistant to digestion by restriction enzymes, which suggests that it might contain atypical
bases or be enzymatically modified. IME15 was the first phage to have its full genome
sequenced, with a genome of ~39 kbp. The second potentially lytic phage to have its whole
genome sequenced was DLP2 with a genome of ~42 kbp in size (Peters et al., 2015). The final
phage described was DLP6. This T4-like phage undergoes pseudolysogeny prior to lytic
activation. The phage genome does not integrate into the host DNA, but proceeds into the lytic
cycle following activation. The genome of DLP6 was sequenced and found to be ~168 kbp
(Peters et al., 2017).
The first step in this thesis research was to isolate a Stenotrophomonas phage from an
environmental sample. Upon isolation, the phage was characterized using molecular and
microbiological techniques. At the time of writing, this thesis research provides the first
assessment of a Stenotrophomonas phage’s effect on its bacterial host’s biofilm. Using an in
vitro model of biofilm formation in the presence or absence of phage, we hypothesized that the
presence of phage significantly inhibits biofilm formation by S. maltophilia
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II. METHODS
Maintenance and Growth of Bacteria
S. maltophilia S18202 was grown and stored on LB (Luria-Bertani) agar. S. maltophilia cultures
were prepared by growing them overnight in LB broth at 37°C with shaking at 235 rpm. Cultures
were standardized to OD600  1.0. Dilutions of culture were added to fresh LB broth and
incubated with agitation at 37°C until exponential growth was obtained (2h). Overnight cultures
were used for phage isolation, plaque enumeration assays, biofilm assays, and host range spot
tests.

Isolation of Bacteriophage
Soil samples were taken from landscaping mulch on the north side of the William G. McGowan
Building on the DePaul University Lincoln Park campus, in Chicago, Illinois. A 10 g sample of
the soil was added to 15 ml of a modified LB suspension medium (SM) (Peters et al., 2015).
After mixing for 1 h on a Stovall Belly Dancer (IBI Scientific) at room temperature (25C), the
sample was centrifuged at 12,000 x g at 25C to remove excess soil debris. The supernatant was
filter sterilized (0.45 m pore size). One hundred microliters of an overnight culture of
S. maltophilia S18202 was added to the filtrate, and was incubated at 37C overnight (Van Twest
and Kropinski, 2009). The mixture was then centrifuged at 12,000 x g for 5 min at 25C. The
liquid supernatant was filter sterilized (0.45 m pore size) and stored at 4C. This preparation
was used as a phage stock for plaque purification.
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Plaque Purification
To purify the virus, a soft agar overlay of the phage sample was performed according to
Kropinski et al. (2009) with modifications from Peters et al. (2015). In microfuge tubes, a 200 l
preparation of S. maltophilia was added to 100 l of phage from a serial dilution of the phage
stock. The virus and bacteria were incubated statically for 8-10 min at 25C. The phage-bacteria
mixture was added to 4 ml of molten soft LB agar (0.4% agar). This was gently swirled and
poured over an LB agar plate. After the soft agar was allowed to solidify, the plates were
incubated at 37C overnight. A single plaque was picked from a plate with isolated plaques by
touching a sterile glass pipette tip to it. The pipette tip was immersed in 500 l of SM with 20 l
of chloroform for 1 h statically at 25C. The chloroform was used to kill any living bacteria
present in the sample. The plaque isolation and purification steps were repeated two subsequent
times to obtain purified phage. The plaque purified stock was used to prepare a high titer stock.

Preparation of High Titer Phage
A soft agar overlay plate with a confluent lawn of plaques (obtained after overnight incubation)
was selected to make the phage stock. Ten milliliters of SM was added to the plate. The plate
was gently agitated on a Stovall Belly Dancer for 1 h. The SM was then removed and added to
microfuge tubes. The tubes were centrifuged at 12,000 x g at 25C for 2 min and the supernatant
was filter sterilized (0.45 m pore size). The purified high titer phage stock was stored at 4C.
This stock was used for the enumeration of the phage. For long-term storage of phage stocks,
purified phage was prepared in 50% glycerol/SM and stored at –80C according to Fortier and
Moineau (2009).
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Enumeration of Phage
Phage titer determination used the soft agar overlay technique and a serial dilution of the high
titer purified phage stock (Kropinski et al., 2009). To a set of microfuge tubes, 200 l of
S. maltophilia was mixed with 100 l of serially diluted phage stock. The samples were
incubated statically for 8-10 min at 25C. The mixture of phage and bacteria was transferred to a
test tube containing 4 ml of molten soft LB agar. The tube contents were then poured over a plate
of LB agar and allowed to solidify. The plates were incubated at 37C overnight. The number of
plaques was recorded and the original concentration of phage stock was determined according to
Equation 1.

Equation 1
(𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 × # 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 𝑝𝑒𝑟 𝑝𝑙𝑎𝑡𝑒)
𝑝𝑙𝑎𝑞𝑢𝑒 𝑓𝑜𝑟𝑚𝑖𝑛𝑔 𝑢𝑛𝑖𝑡𝑠
=
𝑚𝑙
𝑝𝑙𝑎𝑡𝑖𝑛𝑔 𝑣𝑜𝑙𝑢𝑚𝑒

Determining Plaque Size
A plaque assay was performed (see Enumeration of Phage). Plates were incubated overnight at
37 C. The plates were then digitally photographed with a 50 mm ruler for reference. Images of
plaques on a lawn of S. maltophilia S18202 were analyzed using tpsDig software (by F. James
Rohlf, Stony Brook Morphometrics).

Transmission Electron Microscopy
The ultrastructure of the phage was analyzed using the Imaging Facility at the Loyola University
Chicago Health Sciences Campus, Maywood, Illinois. Carbon-coated 200 mesh copper grids
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(Ted Pella, Inc) were treated with 0.002% Alcian Blue in 0.03% acetic acid (Electron
Microscopy Sciences) for 5 min then incubated with distilled water for 5 min to increase the
hydrophilicity of the grids (Chattoraj et al., 1988). Grids were incubated with a high titer sample
of phage (2 x 1011 pfu/ml) in SM for 1 min then stained with filtered 1% uranyl acetate for 1
min. A Philips CM120 transmission electron microscope (voltage = 80 kV) equipped with an
AMT BioSprint camera was used to image the samples. Images of 15 phage particles were used
to acquire measurements of phage ultrastructure. Tail length, tail width, and head diameter were
measured using ImageJ (Schneider et al., 2012).

Phage DNA Analysis
S. maltophilia phage DNA was extracted using the Phage DNA Isolation Kit according to the
manufacturer’s instructions (Norgen Biotek Corporation) and stored at -20°C. The concentration
of purified DNA was determined using a NanoDrop 2000c (Thermo Scientific). Phage DNA was
subjected to restriction enzyme digestion (Table 1). Type II restriction enzymes were used due to
their ability to digest dsDNA. To prepare each restriction enzyme digest, approximately 150-200
ng of DNA were used. The phage DNA digests were subjected to agarose gel electrophoresis at
80V for about 1 h and then visualized using a FlourChem HD2 system (Bio-Techne). Alphaview
software (Bio-Techne) was used to analyze the DNA digests.

Table 1: Restriction enzymes used
BglII
ClaI
EcoRI
KpnI
PstI

PvuII
SalI
SmaI
SphI
XhoI

13

Host Range Analysis
The host range analysis of the S. maltophilia phage was performed according to García et al.
(2008) with the following modifications. The bacterial strains used for the tests are listed in
Table 2. The clinical strains of S. maltophilia were kindly provided by Dr. Stanford Shulman
(Northwestern University). Lawns (confluent growth) of each strain on LB agar plates were
prepared using overnight cultures. Four 5 l drops of phage (~109 pfu/ml) were placed on top of
each agar plate. Plates were incubated at 37C overnight and the presence of clearings were
recorded . Each bacterium was tested in two independent experiments.

Table 2: Bacterial strains used
for host range tests
S. maltophilia
ATCC 13637
ATCC 17807
ATCC BAA-2423
F64644
F7221

H2138
H43306
H59296
S18202
X26332

P. aeruginosa
ATCC 27853
ATCC 22580
ATCC BAA-47

E. coli
ATCC 23922
S. aureus
ATCC 29213

Biofilm Assays
To determine if the purified S. maltophilia phage inhibited biofilm formation of S. maltophilia
S18202, biofilm assays were performed according to Malinowski et al. (2017) with the following
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modifications. After determining the phage titer (see Enumeration of Phage), a dilution was
made to achieve a multiplicity of infection (MOI) of 10, 103, or 105. The MOI is a measure of the
ratio of the number of plaque-forming units to number of colony-forming units (pfu/cfu). To
each well of a 96-well polyvinyl chloride (PVC) microtiter plate (BD Falcon), 50 l of phage in
SM (10mM MgSO4, 50mM Tris-HCl pH 7.5, 100mM NaCl, 50% LB) diluted in LB broth were
added. Fifty microliters of S. maltophilia culture were added to each well. Negative control wells
contained 100 l of LB broth only (no cells or phage). Biofilm plates were incubated statically
for 24 h at 37C. Planktonic cells were removed to a new microtiter plate and the bacterial
culture density was recorded using a spectrophotometer (OD 595). Adhered biofilms were washed
twice with sterile distilled water (dH2O), stained with 0.1% crystal violet for 10 min, washed
three times with sterile dH2O, and air dried overnight at room temperature with minimal light
exposure. The crystal violet was thoroughly resuspended in 30% acetic acid and the amount of
biofilm was recorded at OD560.
When performing the experiments at the MOIs of 10 and 105, each biofilm assay was
performed once, with 5 and 4 replicates, respectively. For the experiment at the MOI of 103, the
biofilm assay was performed in two independent experiments, each with 5 replicates.

Statistical Analysis
In all the biofilm assays, we used a paired t-test to compare means of each treated subculture
with the untreated subculture. The α-values were adjusted using the sequential Bonferroni test
(Holms, 1979). Statistical analyses were performed using Microsoft Excel.
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III RESULTS
Isolation of a S. maltophilia Phage
A S. maltophilia phage was isolated from soil acquired from a horticultural flower bed adjacent
to McGowan North, on DePaul University – Lincoln Park campus. In soft agar overlays of S.
maltophilia S18202 with phage after overnight incubation at 37°C, the phage produced clear
plaques. The size of the plaques ranged from 0.5 – 2.0 mm in diameter (Figure 1). Some plaques
had surrounding halos that were turbid in appearance (Figure 2). The plaque purified phage was
named Stenotrophomonas virus Bfi1 (Biofilm formation inhibitor 1).

Figure 1: Phage plaques formed on a lawn of S. maltophilia S18202. The plate was incubated at
37C overnight on LB agar with a 10-8 dilution of the phage stock. Scale bar = 50 mm.
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Figure 2: Plaque morphology of isolated phage Bfi1. Black arrows highlight plaques with turbid
halos. White arrows highlight plaques without halos. Scale bar = 2 mm.

Bfi1 Ultrastructure
Ultrastructure morphological examination revealed that the phage has a head and an unsheathed
flexible non-contractile tail (Figure 3). The head has an isometric icosahedral shape, with a
diameter of 50.8 ± 5.7 nm. The tail length measures 197.0 ± 31.7 nm. The tail width measures
10.4 ± 1.7 nm.
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Figure 3: Transmission electron micrograph of Stenotrophomonas phage Bfi1, negatively stained
with 1% uranyl acetate. Scale bar = 100 nm.

Phage Genome Analysis
Restriction enzyme (RE) digestion followed with agarose gel electrophoresis demonstrated that
the S. maltophilia phage contains dsDNA. RE analysis of the DNA showed 5 of the 10 type II
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restriction enzymes were able to digest the phage genome: EcoRI, KpnI, SalI, SmaI, and SphI
(Figure 4).

Figure 4: Agarose gel (1%) electrophoresis showing single RE digests of Stenotrophomonas
phage DNA. Lanes: (1) 1 kbp marker, (2) uncut phage DNA, (3) EcoRI, (4) KpnI, (5) SalI, (6)
SmaI, (7) SphI, (8)  phage HindIII marker.
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Digestion of the genome by type II restriction enzymes (EcoRI, KpnI, SalI, SmaI, and
SphI) produced large, well-separated DNA bands (Table 3). Using the AlphaView software to
analyze the DNA fragments, the size of the phage genome was estimated to be 32.2-56.5 kbp.
This was done by adding the fragment sizes of each band from individual digests to get a total
DNA size.

Table 3: Bfi1 single RE digest DNA sizes
DNA fragment length (bp)

Band
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Total

EcoRI
19027
14377
6800
5550
4567
2833
1950
1436
56540

KpnI
19027
7800
7000
6267
5700
2307
48101

SalI
7067
5800
4333
3825
1550
1447
1340
1048
936
801
736
656
594
534
458
402
366
314
32207

SmaI
8083
5000
4700
4267
3725
3211
2409
2307
2170
1517
1000
881
771
588
460
428
306
41823

SphI
9833
8833
7467
6467
5400
3625
2648
2027
1858
1583
1330
1074
949
831
53925

Host Range Analysis
The host range of this phage was assessed using available strains of S. maltophilia,
P. aeruginosa, Escherichia coli, and Staphylococcus aureus (Table 4 and Figure 5). Of the
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bacteria tested, 30% of the S. maltophilia strains (S18202, H2138, H43306) were infected by the
phage (as indicated by phage generated clearings formed within the lawn of bacteria), and the
remainder of the bacteria were resistant to infection (as indicated by the absence of clearings).
These observations indicate that S. maltophilia phage Bfi1 has a moderate host range.

Table 4. Host range of Bfi1
Bacterial strain

Infection by phage*

S. maltophilia
ATCC 13637
ATCC 17807
ATCC BAA-2423
F64644
F7221
H2138
H43306
H59296
S18202
X26332
P. aeruginosa
ATCC 27853
ATCC 22580
ATCC BAA-47
E. coli
ATCC 23922
S. aureus
ATCC 29213
* + phage infection, - no infection
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+
+
+
-

B

A

Figure 5: Bfi1 spot tests of S. maltophilia strains. (A) Strain H2138 shows infectivity and (B)
strain H59269 shows no infectivity by the phage.

Phage Inhibition of S. maltophilia Biofilm Formation
Following a 24 h incubation of S18202 in a microtiter plate, liquid medium containing
planktonic cells was removed and the cell density of the media quantified by spectrophotometry
(OD595). At an MOI=10 (actual MOI≈5.1) a significant inhibition of planktonic cell culture
density was observed (Figure 6A). Inhibition of planktonic cell growth was also observed at an
MOI=103 (actual MOI≈1.8x103) and an MOI=105 (actual MOI≈1.5x105) (Figure 6B, C).
The amount of biofilm formed on the microtiter plate surface was determined using the
crystal violet assay. The difference in the amount of biofilm formed was not statistically
significant at MOI=10 (Figure 7A). At MOI=103 and MOI=105, the amount of biofilm formed
was significantly reduced in the phage treatment groups (Figure 7B, C).
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A

0.6

OD 595 nm

0.5

*

0.4
0.3
0.2
0.1
0
Untreated

B

Treated

0.6

*

0.5

OD 595 nm

0.4
0.3
0.2
0.1
0
Untreated

C

Treated

0.6

*

0.5

OD595 nm

0.4
0.3
0.2
0.1
0
Untreated

Treated

Figure 6: Planktonic cell culture density (OD 595) of S. maltophilia after 24 h treatment with
phage Bfi1, (A) MOI=10 (B) MOI=103 (C) MOI=105 . Vertical bars represent standard error.
(*) indicates statistical significance of paired t-tests adjusted using a sequential Bonferroni test
for multiple comparisons. (A) p = 2.1 x 10-2, (B) p = 5.7 x 10-8, (C) p = 1.1 x 10-3
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A
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Untreated

B

Treated
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OD 560 nm
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0.4
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0.2
0.1
0
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*
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0.5
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Figure 7: Amount of biofilm formed (OD560) of S. maltophilia after 24 h treatment with phage
Bfi1, (A) MOI=10 (B) MOI=103 (C) MOI=105 . Vertical bars represent standard error.
(*) indicates statistical significance of paired t-tests adjusted using a sequential Bonferroni test
for multiple comparisons. (A) p = 0.75, (B) p = 5.9 x 10-4, (C) p = 1.2 x 10-3
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IV. DISCUSSION
S. maltophilia Bacteriophage Bfi1
S. maltophilia bacteriophage, Bfi1, was successfully isolated from a local soil sample. Initially,
plaques were harvested and purified. The purified phage was further characterized using
transmission electron microscopy, and its genome was analyzed using restriction enzyme
digestion with agarose gel electrophoresis.

Plaque Morphology
Phage Bfi1 was able to form circular plaques, ranging from 0.5 – 2.0 mm in diameter (Figure 1).
Plaque size is affected by a variety of factors including the virus’s diffusivity, adsorption rate,
latent period, and burst size (Abedon and Yin, 2009; Gallet et al., 2011). Diffusivity is a measure
of the capability for a particle to be diffused. Adsorption rate is the rate at which plaque-forming
units attach to susceptible host cells. The latent period is the infection time, between adsorption
and host cell lysis. Burst size is defined as the number of new plaque-forming units produced
when an infected cell lyses. The variation in plaque size within a single phage strain may be due
to subtle differences in the genotypes that resulted from random mutations during replication.
These differences could affect the burst size, adsorption rate, latent period and diffusivity of the
phage.
Some phages can reduce biofilms by producing enzymes that break up extracellular
polymers. These enzymes, called depolymerases have been shown to be important in biofilm
penetration (Casey et al., 2018). One indicator that a phage may possess a depolymerase is
through analysis of plaque morphology. The plaques of depolymerase-expressing phages are
often surrounded by a large halo, which indicates depolymerase activity (Hughes et al., 1998).
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Since there were halos surrounding some of the phage derived plaques (Figure 2), S. maltophilia
phage Bfi1 may produce depolymerases.

Ultrastructure of Bfi1
Table 5 shows the ultrastructural diversity of bacteriophages. One third of the phages shown
contain a tail. Tailed phages (Order: Caudovirales) are considered the most abundant phages
found in nature (Ackermann, 2007). Of ~5500 phages documented using electron microscopy
and submitted to the Félix d’Hérelle Reference Center for Bacterial Viruses, 96% of them were
described as tailed phages (Ackermann, 2007). The phage tail is an appendage that is used in
host receptor recognition, penetration of the cell wall and ejection of the virus genome into the
host cell (Fokine and Rossman, 2014).
The Caudovirales order is divided into four families, Ackermannviridae, Myoviridae,
Podoviridae, and Siphoviridae (Ackermann, 2009; Adriaenssens et al., 2018) Morphologically,
Ackermannviridae and Myoviridae are indistinguishable, both possessing long sheathed
contractile tails (Adriaenssens et al., 2018). Podoviridae possess short stubby non-contractile
tails. Long unsheathed flexible non-contractile tails are a hallmark of the Siphoviridae family
(Ackermann, 2009).
We compared the tail ultrastructure of 15 Bfi1 virions to the four families of
Caudovirales. The tail length of Bfi1 is 197.0 ± 31.7 nm , which is much longer than the tail
length of Podoviridae phages (20 nm) (King et al., 2012). Therefore, it is unlikely that Bfi1
belongs to Podoviridae. The tail width of Bfi1 is 10.4 ± 1.7 nm. This falls within the description
of Siphoviridae phages, which have tail widths of 7-10 nm (King et al., 2012). The tail widths of
Myoviridae and Ackermannviridae phages (16-20 nm) are much thicker than the tail of Bfi1
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(King et al., 2012). When considering that Bfi1 also has a flexible tail (Figure 3), our
observations lead us to conclude that Bfi1 is most likely a member of the Siphoviridae family
within the Caudovirales order.

Table 5: Overview of bacteriophage families
Family

Description of Ultrastructure

Nucleic Acid

Myoviridae

long sheathed contractile tail
length: 80-455 nm; width:16-20 nm

dsDNA linear

Ackermannviridae

long sheathed contractile tail
length: 80-455 nm; width: 16-20 nm

dsDNA linear

Siphoviridae

long unsheathed flexible non-contractile tail
length: 65-570 nm; width: 7-10 nm

dsDNA linear

Podoviridae

short non-contractile tail
length: 20 nm; width: 8 nm

dsDNA linear

Tectiviridae

isometric, double capsid

dsDNA linear

Corticoviridae

isometric capsid

dsDNA circular

Plasmaviridae

enveloped, no capsid, pleomorphic

dsDNA circular

Sphaerolipoviridae isometric capsid

dsDNA linear

Inoviridae

long filaments or short rods

ssDNA circular

Microviridae

conspicuous capsomers, isometric capsid

ssDNA circular

Leviviridae

isometric capsid

ssRNA linear

Cystoviridae

enveloped, spherical

dsRNA segmented

(Ackermann, 2009; King et al., 2012; Adriessens et al., 2018)
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S. maltophilia Phage Bfi1 Genome
The Caudovirales order is additionally unique in that their dsDNA is linear (Ackermann,
2009). This appears to be a result of the virion structure. To package DNA into a capsid and eject
the genome from it, the DNA must be threaded through a narrow passage in the head portal. This
passage is too small to accommodate two parallel dsDNAs simultaneously (as would be needed
in the case of a circular genome) (Casjens and Gilcrease 2009). As S. maltophilia phage Bfi1
appears to be a member of the Caudovirales order, we can infer that the phage in this study is
likely to have a linear genome.
The type II restriction enzyme digestions of the S. maltophilia phage Bfi1 genome
indicate that the phage genome is dsDNA, as these enzymes are only able to cut this type of
nucleic acid (Figure 4). Restriction enzyme analysis determined the size of the genome to 32.256.5 kb (Table 3). A more accurate determination of the size would result from fully sequencing
the genome. Genomic sequencing can be done using a shotgun cloning protocol (Lynch et al.,
2010).
Without genomic sequencing, this DNA analysis did not generate enough information for
us to conclusively identify the novelty of this phage. According to the International Committee
on the Taxonomy of Viruses (ICTV), the major basis for distinguishing a new species of virus
requires evidence that its genome sequence identity be less than 95% similar to its closest
taxonomic relative (Adriaenssens and Brister, 2017). Until the genome of this phage is
sequenced, the Bacterial and Archaeal Virus Subcommittees within the ICTV will not be able to
affirm the novelty of this phage.
Taken together, the ultrastructure and genome analyses of S. maltophilia phage Bfi1
support its classification as a siphovirus within the Caudovirales order.
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S. maltophilia Siphoviruses
At the time of writing, Bfi1 is the sixth Siphoviridae phage to be characterized that
infects S. maltophilia. Table 6 describes all S. maltophilia siphoviruses described in the
literature.
Table 6: S. maltophilia siphoviruses
Phage

Head Diameter
(nm)

S1
S4
DLP1
DLP2
DLP5
Bfi1

61.4 ± 1.35
87.5 ± 1.5
~70
~70
NA
50.8 ± 5.7

Tail Length
(nm)

Tail Width
(nm)

129.2 ± 1.3
201.87 ± 1.22
~175
~205
NA
197.0 ±31.7

9.93 ± 0.66
10.7 ± 0.24
NA
NA
NA
10.4 ± 1.7

Genome
size (kbp)
40.287
~200
42.887
42.593
96.542
32.2-56.5

Reference
García et al., 2008
García et al., 2008
Peters et al., 2015
Peters et al., 2015
Peters and Dennis, 2018
This study
*NA, not available

García et al. (2008) reported two temperate siphoviruses that have a S. maltophilia host,
S1 and S4. S1 was discovered by induction of a lysogen using mitomycin C. S4 was acquired
from sewage samples. Peters et al. (2015) identified two S. maltophilia siphoviruses, DLP1 and
DLP2. DLP1 was isolated from river sediment DLP2 was isolated from soil. DLP1 has a unique
plaque development; at high titers (1010 pfu/ml) no plaques form. At lower titers, plaques were
turbid with no distinct borders. DLP2 produces plaques with distinct borders. Neither phages
contain any recognizable lysogeny-associated proteins in its genome. However, due to the
irregular plaque formation, DLP1 is likely a lysogenic phage. Based on this data, DLP2 might be
lytic, but this has not been confirmed experimentally. As of the writing of this thesis, there is not
much information available on DLP5, but it was shown to be lysogenic (Peters and Dennis,
2018).
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In comparing Bfi1 to other siphoviruses, we can see that our phage appears similar to
others in tail size and length, while it has a smaller head diameter (Table 6). There is a large
range of genome sizes for S. maltophilia siphoviruses, but Bfi1 falls within this range. With the
current data, it is not possible to determine if Bfi1 is lytic or lysogenic. However, it is possible
that this represents the first lytic S. maltophilia siphovirus to be described.
Lysogenic abilities can be assessed by characterizing the phage genome. Lysogenyassociated proteins, such as integrases and lytic cycle repressors are often readily identifiable
(Casey et al., 2018). Lysogeny can also be tested experimentally by taking colonies that acquire
phage resistance and testing the host genome for the presence of a prophage.

Host Range of Bfi1
The process of host cell lysis involves the adsorption of the phage to the host receptor (Labrie et
al., 2010). After adsorption, the phage genome is ejected into the host. Replication of the phage
genome and virion structure occurs during the latent period. Lysis occurs at the end of infection
and viral progeny are released into the surrounding media (Labrie et al., 2010). The progeny
viruses start the infection process over in neighboring host cells. Eventually enough cells are
killed that a clearing is visible to the naked eye. The exact timing of this process, can be
determined by performing a one-step growth assay. This can be useful information when looking
at lytic activity of a phage and is an important feature of phage characterization.
The first step in the phage infection cycle, adsorption, is the initial point of contact
between virus and host and dictates host range specificity (Silva et al., 2016). Caudovirales
phages recognize hosts using their tail structures, which have phage receptor-binding proteins
(RBPs) which can recognize specific peptide sequences or polysaccharide moieties (Silva et al.,

30

2016). A phage fails to effectively infect a strain when the host receptors are inaccessible or noncomplementary to the phage RBPs (Silva et al., 2016). Of Siphoviridae phages studied with
Gram-negative bacterial hosts, 16 recognized proteinaceous receptors and 3 required a
combination of proteins and sugar moieties (Silva et al., 2016).
The moderate host range of 30% for S. maltophilia phage Bfi1 is based on only 10 strains
of S. maltophilia (Table 4). Because the number of strains tested in this research was relatively
small, it may not be reflective of the true host range of this phage. Ideally, we would develop an
expansive S. maltophilia collection, containing a variety of pathogenic strains which would
represent a breadth of genetic diversity within this species.
The host ranges of other Stenotrophomonas lytic phages are highlighted in Table 7. These
host ranges could all be described as moderate, ranging from 30% to 70% of strains tested. It
should be remarked that DLP2 formed plaques on two P. aeruginosa strains as well (Peters et al.,
2015). The ability of the mentioned phages to infect hosts from different taxonomic orders is not
typical.

Table 7: Host range of lytic and pseudolysogenic S. maltophilia phages
Phage
phiSMA5
Smp14
S3
DLP2
DLP6
Bfi1

Family
Myoviridae
Myoviridae
Myoviridae
Siphoviridae
Myoviridae
Siphoviridae

Host Range

Strains Tested

Reference

70%
56%
46%
33%

10
87
26
27

Chang et al., 2005
Chen et al., 2007
García et al., 2008
Peters et al., 2015

48%
30%

27
10

Peters et al., 2017
This Study

The limited host range of S. maltophilia phages might be attributed to the considerable
diversity of this host species. In comparing the genome of ATCC BAA-2423 (K279a, a
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pathogenic strain) to R551-3 (a plant endosymbiotic strain), approximately 85% of the R551-3
strain’s 4,175 genes were homologous to the pathogenic strain (Ryan et al., 2009). This leaves
hundreds of divergent genes between these two strains. Even between pathogenic isolates there is
considerable diversity. A study of 139 S. maltophilia isolates from the same hospital found that
there was considerable phylogenetic and phenotypic variability between isolates (Valdezate et
al., 2004). If host susceptibility can be blocked by modifications to a single receptor gene, then
the diversity within the species S. maltophilia may explain the limits to the host range of these
Stenotrophomonas phages.
The type of host receptor that is recognized by S. maltophilia phage Bfi1 has not been
determined. Understanding the host receptors needed for phage infection of Stenotrophomonas
maltophilia may be informative in understanding why the host range is moderate. This could be
tested by developing a mutant library of S18202 and determining which gene(s) is/are necessary
for phage infection.
Host receptor recognition is not the only component of host range specificity, but it is a
major avenue to acquire resistance against viral infections (Rodriguez-Valera et al., 2009).
Bacterial hosts can employ a variety of other mechanisms to block phage infection. These
include: superinfection exclusion systems, restriction-modification systems, Argonaute proteins,
CRISPR-Cas systems, abortive infection systems, and toxin-antitoxin systems (Dy et al., 2014).
S. maltophilia phage Bfi1 was tested against P. aeruginosa, a related pathogen (Williams
et al., 2010). Based on observations by Peters et al. (2015) we know that there are some phages
that infect both S. maltophilia and P. aeruginosa. There are limited examples of phages with this
wide of a host range, so we did not expect to observe plaque formation by Bfi1 on P. aeruginosa.
Regardless of our expectations, it is medically relevant to test this because P. aeruginosa and
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S. maltophilia are often found together in polymicrobial communities (Berg et al., 2005). Most
notably these bacteria can coinfect the CF patient’s lungs (Graff and Burn, 2002).
Other organisms that are phylogenetically related to Stenotrophomonas maltophilia, may
also be susceptible to phage Bfi1, including those of the Xanthomonas and Xylella genera
(Williams et al., 2010). Both these genera harbor debilitating plant pathogens of agricultural
significance, such as black rot (affecting cruciferous vegetables like cabbage and broccoli)
(Williams, 1980) and Pierce’s disease (a lethal grapevine disease) (Hopkins and Purcell, 2002). It
may be significant to consider the effect of Bfi1 on these pathogens due to their economic and
agricultural harm.

Phage-Biofilm Interactions
To the best of our knowledge, this is the first time the effects of a phage on S. maltophilia
biofilms have been studied. From the biofilm assays, we demonstrated that the phage, at an
MOI=103, inhibits the development of biofilms when it is introduced simultaneously with
planktonic cells in culture (Figure 7B). This effect is even greater at MOI=105 (Figure 7C). At
MOI=10 there was only a small effect on the planktonic cell culture of the bacteria (Figure 6A).
There is no effect on the S. maltophilia biofilms at MOI=10 (Figure 7A). One explanation is that
at a lower titer the host has enough time to begin to form phage-resistant biofilms. A higher titer
of phages kills more cells before biofilm formation is underway, whereas a lower titer of phages
allows more cells to begin to establish biofilms on the polyvinyl chloride surface.
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Potential Use in Therapy
At the time of writing this thesis, no S. maltophilia phages have been used in any form of
therapy. There is still much more information needed to determine if this phage should be
recommended therapeutically. First, it will be necessary to confirm that the phage is lytic. At this
point, the phage has not been definitively shown to be lytic or lysogenic. This is a significant
consideration because lysogenic phages are not considered good candidates for phage therapy.
Lysogenic phages can convert hosts into lysogens, preventing these hosts from undergoing
immediate lysis and making the host phage-resistant (Casey et al., 2018).
Lysogens can also result in other phenotypic changes to their host that may enhance host
virulence. For example, the Liverpool Epidemic Strain of P. aeruginosa contains multiple
prophages that have been shown to confer enhanced virulence to their host (Salunkhe et al.,
2005). In the same way, the Vibrio phage CTXphi carries the cholera toxin, which is required for
the pathogen, Vibrio cholerae, to trigger toxin-mediated epidemic cholera (Waldor and
Mekalanos, 1996).
A similar but separate concern in identifying phages useful in therapy is the horizontal
gene transfer of virulence factors such as toxins (Pirnay et al., 2015). Genome sequencing may
also allow us to rule out phages that carry toxins or antibiotic resistance factors. Even if a phage
is not lysogenic, it may be risky to introduce a genetic element that could exacerbate an
infection. Many bacteria, including S. maltophilia, are naturally competent and able to take up
DNA from their environment (Berg and Martínez, 2015). Therefore, there is a risk that virulence
genes could be acquired from a phage without lysogenic conversion.
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Phage Resistance of Biofilms
The steps towards effective therapies require evidence of the efficacy of a phage treatment. This
research has shown that biofilm formation is significantly affected by S. maltophilia phage Bfi1.
However, the biofilm experiments in this thesis were performed in vitro, and in a patient, S.
maltophilia biofilms may respond differently to phage treatment. Research on other bacterial
pathogens indicate that biofilms may demonstrate resistance to phage. An in vivo mouse study
using P. aeruginosa strain PAK demonstrated that a phage treatment 2 h post-infection resulted
in 100% survival. However, this survival rate dropped down to 20% at 6 h post-infection
(Debarbieux et al., 2010). The data in this study suggest that immature biofilms may be more
susceptible to phage than fully developed mature biofilms. Therefore, it is important to design a
therapy that anticipates the different stages of a biofilm. Future research with the S. maltophilia
phage Bfi1 can address this by assessing the phage’s effect on a mature biofilm, or through a
time-course study of biofilm development.
There are a few reasons to explain why a biofilm might confer viral resistance. In some
cases, biofilms cause phage resistance by preventing phage from reaching the host cells.
Between the lytic T7 phage and its host E. coli biofilm, the protection from phage was due to
prevention of phage transport into the biofilm and through competitive inhibition of the phage
receptor by curli polymers (an amyloid fiber network) (Vidakovic et al., 2017). In other words,
the phage was adhering to the extracellular polymers instead of adsorbing to the cells.
Phase variation observed during biofilm maturation may also be involved in phage
resistance. Phase variation involves changes of protein expression within a bacterial population.
As the biofilm-forming phenotypes will involve changes in the proteins expressed on the cell
surface, the proteins required for adsorption may not be present on cells within a biofilm. As an
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example of phase variation resistance, Bordetella species is 106 times more susceptible to phage
BPP1 when pertactin, an adhesion protein, is expressed (Liu et al., 2002). This protein is
expressed in much higher quantities during the virulent phase, when certain adhesins, toxins, and
secretion systems are activated (Liu et al., 2002).

Phage Therapy
The research on phage therapy for treatment of bacterial infections has grown substantially in
recent years. S. maltophilia phage Bfi1 may be useful in such treatments. While it may not
demonstrate a broad host range, this phage could be tested in combination with other approaches
to treat Stenotrophomonas infections.
Using multiple phages in a phage cocktail (termed polyphage therapy) may offer benefits
that a monophage treatment cannot. Use of phage cocktails can solve two difficulties presented
to clinicians: the limited host range and the development of phage resistance. By combining
multiple phages that each have a different host range, there are greater chances that a strain of
bacteria will be susceptible to one or more of the phages in the cocktail. For example, Alves et
al. (2015) reported that a phage cocktail in vitro led to 100% inhibition of Pseudomonas PAO1
after 24 h. In contrast, Pseudomonas PAO1 began re-growing after 8 h following each
monophage treatment. Phage resistance can evolve naturally among host bacteria through genetic
mutation, but using multiple phages should reduce the possibility that bacterial mutants become
multi-phage resistant.
It is important to acknowledge that polyphage therapy is not a perfect solution. In a study
by Gu et al. (2012), the authors demonstrated the development of phage-resistant mutants of
Klebsiella pneumoniae strain K7, even when treated with a three phage cocktail. It should be
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noted that regrowth of K. pneumoniae from individual phage treatments was detected between 68 h, while regrowth from the phage cocktail occurred at 26 h. Although phage-resistance remains
a concern in polyphage therapy, it is greatly reduced.
Another consideration, which was highlighted earlier, is that not all phages are
innocuous. Some bacterial viruses can enhance the virulence of their hosts. This same concern
exists and could be heightened in polyphage treatments. For example, one phage may confer
resistance to other phages in a cocktail. This concern can be alleviated by requiring substantial
characterization of prospective phages prior to their application. Bioinformatic techniques, which
allow for rapid identification of undesirable genetic elements, can begin to eliminate phages from
use that possess such characteristics (Chan et al., 2013).
Another emerging approach to phage therapy is the combination of phages with
antibiotics to enhance phage virulence. The addition of a low dosage of the cephalosporin,
cefotaxime with Escherichia phage phiMFP results a seven-fold increase in burst size compared
to the phage by itself (Comeau et al., 2007). This phenomenon, referred to as phage-antibiotic
synergy (PAS), has been demonstrated in phages of P. aeruginosa and Burkholderia cepacia
complex, as well (Knezevic et al., 2013; Kamal and Dennis, 2015). It is difficult to identify the
benefit and drawbacks for this approach currently, due to the limited data available.
In the United States, the pathway for phage therapy development includes a series of
steps that have not yet been surmounted. The current process for the development of
conventional medicinal products may not be compatible with timely phage therapy development
(Pirnay et al., 2015). But most experts can agree that phages used in therapies require a complete
characterization of their physiology, genetics, and pharmacological potential (Forde and Hill,
2018). Only after these steps, should the production and regulation of a therapy be considered.
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Conclusion
There are still important research questions that must be addressed before we can
definitively recommend this phage for such a therapy. We need to show that the phage is lytic,
that its genome does not carry virulence factors, and demonstrate that it can be useful in treating
biofilms, either by itself or in combination with other phages or antibiotics. With a growing
prevalence of S. maltophilia infections, and the steady rise of antibiotic resistance, there is an
urgent need for alternative treatments of this pathogen.

38

REFERENCES
Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. 2011. Phage treatment of human infections.
Bacteriophage. 1:66–85.
Abedon ST, Yin J. 2009. Bacteriophage plaques: theory and analysis. Methods Mol Biol 501:161174.
Ackermann HW. 2007. 5500 Phages examined in the electron microscope. Arch Virol 152:22743.
Ackermann HW. 2009. Phage classification and characterization. Methods Mol Biol 501:127-40.
Adrianenssens EV, Brister JR. 2017. How to name and classify your phage: an informal guide.
Viruses 9:70.
Adriaenssens EM, Wittmann J, Kuhn JH, Turner D, Sullivan MB, Dutilh BE, Jang HB, van Zyl
LJ, Klumpp J, Lobocka M, Moreno Switt AI, Rumnieks J, Edwards RA, Uchiyama J,
Alfenas-Zerbini P, Petty NK, Kropinski AM, Barylski J, Gillis A, Clokie MRC,
Prangishvili D, Lavigne R, Aziz RK, Duffy S, Krupovic M, Poranen MM, Knezevic P,
Enault F, Tong Y, Oksanen HM, Brister JR. 2018 Taxonomy of prokaryotic viruses:
2017 update from the ICTV Bacterial and Archaeal Viruses Subcommittee. Arch Virol
163:1125-9.
Alonso A, Martinez JL. 2000. Cloning and characterization of SmeDEF, a novel multidrug efflux
pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 44:3079-86.
Alves DR, Perez-Esteban P, Kot W, Bean JE, Arnot T, Hansen LH, Enright MC, Jenkin ATA.
2015. A novel bacteriophage cocktail reduces and disperses Pseudomonas aeruginosa
biofilms under static and flow conditions. Microb Biotechnol 9:61-74.

39

Ashelford KE, Day MJ, Fry JC. 2003. Elevated abundance of bacteriophage infecting bacteria in
soil. App Env Microbiol 69:285-96.
Araoka H, Baba M, Yoneyama A. 2010. Risk factors for mortality among patients with
Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009. Eur J Clin
Microbiol Infect Dis 29:605-8.
Berg G, Eberl L, Hartmann A. 2005. The rhizosphere as a reservoir for oppurtunistic human
pathogenic bacteria. Environ Microbiol 7:1673-85.
Berg G, Martinez JL. 2015. Friends or foes: can we make a distinction between beneficial and
harmful strains of the Stenotrophomonas maltophilia complex? Front Microbiol 6:241.
Berg G. 2009. Plant-microbe interactions promoting plant growth and health: perspectives for
controlled use of microorganisms in agriculture. Appl Microbiol Biotechnol 84:11-8.
Brooke JS. 2012. Stenotrophomonas maltophilia: an emerging global oppurtunistic pathogen. Clin
Microbiol Rev 25:2-41.
Burrowes B, Harper DR, Anderson J, McConville M, Enright MC. 2011. Bacteriophage therapy:
potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther
9:775-85.
Casey E, van Sinderen D, Mahony J. 2018. In vitro characteristic of phages to guide ‘real life’
phage therapy suitability. Viruses 10:163.
Casjens SR, Gilcrease EB. 2009. Determining DNA packaging strategy by analysis of the
termini of the chromosomes in tailed-bacteriophage virions. Methods Mol Biol 502:91111.
Champoux JJ. 2001. DNA topoisomerases: structure, function, and mechanism. Annu Rev
Biochem 70:369-413.

40

Chan BK, Abedon ST, Loc-Carillo C. 2013. Phage cocktails and the future of phage therapy.
Future Microbiol 8:769-83.
Chang HC, Chen CR, Lin JW, Shen GH, Chang KM, Tseng YH, Weng SF. 2005. Isolation and
characterization of novel giant Stenotrophomonas maltophilia phage phiSMA5. Appl
Environ Microbiol 71:1387-93.
Chang Y, Lin C, Chen Y, Hsueh P. 2015. Update on infections caused by Stenotrophomonas
maltophilia with particular attention to resistance mechanisms and therapeutic options.
Frontiers in Microbiology. 6:893.
Chattoraj SN, Mason RJ, Wickner SN. 1988. Mini-P1 plasmid replication: the autoregulationsequestration paradox. Cell 52:551-7.
Chen CR, Lin CH, Lin JW, Chang CI, Tseng YH, Weng SF. 2007. Characterization of a novel T4type Stenotrophomonas maltophilia virulent phage Smp14. Arch Microbiol 188:191-7.
Cho SY, Kang CI, Kim J, Ha YE, Chung DR, Lee NY, Peck KR, Song JH. 2014. Can levofloxacin
be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas
maltophilia bacteremia? Antimicrob Agents Chemother 58:581-3.
Comeau AM, Tétart F, Troject SN, Prère MF, Krisch HM. 2007. Phage-Antibiotic Synergy
(PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One
2:e799.
Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent
infections. Science 284:1318-22.
Crossman LC, Gould VC, Dow JM, Vernikos GS, Okazaki A, Sebaihia M, Saunders D,
Arrowsmith C, Carver T, Peters N, Adlem E, Kerhornou A, Lord A, Murphy L, Seeger K,
Squares R, Rutter S, Quail MA, Rajandream MA, Harris D, Churcher C, Bentley SD,

41

Parkhill J, Thomson NR, Avison MB. 2008. The complete genome, comparative and
functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded
by drug resistance determinants. Genome Biol 9:R74.
de Oliveira-Garcia D, Dall'Agnol M, Rosales M, Azzuz AC, Alcantara N, Martinez MB, Giron
JA. 2003. Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and
to abiotic surfaces. Cell Microbiol 5:625-36.
Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. 2010.
Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect
Dis 201:1096-104.
DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. 2016. Current understanding of dysbiosis in
disease in human and animal models. Inflamm Bowel Dis 22:1137-1150.
Denton M, Rajgopal A, Mooney L, Qureshi A, Kerr KG, Keer V, Pollard K, Peckham DG, Conway
SP. 2003. Stenotrophomonas maltophilia contamination of nebulizers used to deliver
aerosolized therapy to inpatients with cystic fibrosis. J Hosp Infect 55:180-3.
Donlan RM. 2002. Biofilm: microbial life on surfaces. Emerg Infect Dis 8:881-90.
Dy RL, Richter C, Salmond GPC, Fineran PC. 2014. Remarkable mechanisms in microbes to resist
phage infection. Annu Rev Virol 1:307-31.
Falagas ME, Kastoris AC, Vouloumanou EK, Dimopoulos G. 2009. Community-acquired
Stenotrophomonas maltophilia infections: a systematic review. Eur J Clin Microbiol Infect
Dis 28:719-30.
Farrell DJ, Sader HS, Jones RN. 2010. Antimicrobial susceptibilities of a worldwide collection of
Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly
used for S. maltophilia infections. Antimicrob Agents Chemother 54:2735-7.

42

Fokine A, Rossman MG. 2014. Molecular architecture of tailed double-stranded DNA phages.
Bacteriophage 4:e28281.
Forde A, Hill C. 2018. Phages of life — the path to pharma. Brit J Pharmacol 175:412-8.
Fortier LC, Moineau S. 2009. Phage production and maintenance of stocks, including expected
stock lifetimes. Methods Mol Biol 501:203-19.
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